Disease Management and Health Outcomes

, Volume 8, Issue 3, pp 147–158

Smoking Cessation

The Contribution of Community Pharmacy
  • James C. McElnay
  • Terry A. Maguire
  • Ashlinn Drummond
  • Carmel M. Hughes
Review Article

Abstract

Smoking accounts for significant morbidity and mortality and has major economic consequences for healthcare delivery throughout the world. Government policy such as increasing taxes and restricting advertising go some way to reduce smoking, but the social and economic factors that affect target populations will impact on the success of any strategy.

Public health interventions can also contribute to increasing cessation rates. The most successful interventions appear to be those characterised by personalised advice and assistance, repeated in different forms over the longest feasible period of time. Pharmacological aids, which are important components of a cessation programme, include nicotine replacement therapy in the form of chewing gum, patches, nasal spray, oral inhaler or sublingual tablets; bupropion (amfebutamone) has been approved for use in some countries. As the community pharmacy is the major point of supply of such products, the pharmacist is in a key position to encourage and support clients who wish to stop smoking.

A number of studies have examined the role of the community pharmacist in assisting smokers through the so-called ‘cycle of change’. These studies have utilised a model that offers individualised advice through a motivational technique to encourage a change in behaviour; nicotine replacement therapy is optional. Follow-up is an essential part of these programmes to monitor progress and to provide additional support. Evaluations of these pharmacy-based initiatives have confirmed the importance of a multifaceted approach in achieving success in smoking cessation, i.e. behaviour modification, nicotine replacement therapy and client support.

References

  1. 1.
    Office of Population, Censuses and Surveys. General Household Survey, London: Her Majesty’s Stationary Office, 1992Google Scholar
  2. 2.
    Office of Population, Censuses and Surveys. General Household Survey, London: Her Majesty’s Stationary Office, 1994Google Scholar
  3. 3.
    Amos A. Women and smoking. Br Med Bull 1996; 52: 74–89PubMedCrossRefGoogle Scholar
  4. 4.
    Evans N, Farkas A, Gilpin E, et al. Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. J Natl Cancer Inst 1995; 87: 1538–45PubMedCrossRefGoogle Scholar
  5. 5.
    Feighery E, Borzekowski DLG, Schooler C, et al. Seeing, wanting, owning: the relationship between receptivity to tobacco marketing and smoking susceptibility in young people. Tobacco Control 1998; 7: 123–8PubMedCrossRefGoogle Scholar
  6. 6.
    Pucci LG, Siegal M. Exposure to brand-specific cigarette advertising in magazines and its impact on youth smoking. Prev Med 1999; 29: 313–20PubMedCrossRefGoogle Scholar
  7. 7.
    Peto R, Darby S, Deo H, et al. Smoking, smoking cessation and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321: 323–9PubMedCrossRefGoogle Scholar
  8. 8.
    Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994; 309: 937–9PubMedCrossRefGoogle Scholar
  9. 9.
    Chapman S. Smokingin the workplace. Lancet 1992; 339: 1614PubMedCrossRefGoogle Scholar
  10. 10.
    Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years’ observation on male British doctors. BMJ 1994; 309: 901–11PubMedCrossRefGoogle Scholar
  11. 11.
    Godfrey C, Edwards H, Raw M, et al. The smoking epidemic: a prescription for change. London: Health Education Authority, 1993Google Scholar
  12. 12.
    Maguire TA. Smoking cessation: a model for UK community pharmacists. Int J Smoking Cessation 1996; 4: 239–40Google Scholar
  13. 13.
    Benowitz NL. Cigarette-smoking and nicotine addiction. Med Clin North Am 1992; 76: 415–37PubMedGoogle Scholar
  14. 14.
    Henningfield JE, Schuh LM, Jarvik ME. Pathophysiology of tobacco dependence. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd., 1995: 1715–29Google Scholar
  15. 15.
    Austoker J, Sanders D, Fowler G. Smoking and cancer: smoking cessation. BMJ 1994; 308: 1478–82PubMedCrossRefGoogle Scholar
  16. 16.
    Zang EA, Wynder EL. Smoking trends in the United States between 1969 and 1995 based on patients hospitalised with non-smoking related diseases. Prev Med 1998; 27: 854–61PubMedCrossRefGoogle Scholar
  17. 17.
    Anon. State-specific prevalence of current cigarette and cigar smoking among adults — United States, 1998. Morb Mortal Wkly Rep 1999; 48: 1034-9Google Scholar
  18. 18.
    Mackay J, Crofton J. Tobacco and the developing world. Br Med Bull 1996; 52: 206–21PubMedCrossRefGoogle Scholar
  19. 19.
    The Health Education Authority. The smoking epidemic: a prescription for change, London: The Health Education Authority, 1991Google Scholar
  20. 20.
    Kottke TE, Solberg LI, Brekke ML, et al. Smoking cessation strategies and evaluation. J Am Coll Cardiol 1988; 12: 1105–10PubMedCrossRefGoogle Scholar
  21. 21.
    Elixhauser A, Eisen SA, Romeis JC, et al. The effects of monitoring and feedback on compliance. Med Care 1990; 28: 882–93PubMedCrossRefGoogle Scholar
  22. 22.
    Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville (MD): US Department of Health and Human Services, Public Health Service, 2000 JunGoogle Scholar
  23. 23.
    Maguire TA. A study of the feasibility of a smoking cessation service in a community pharmacy. Pharm J 1993; 251: R26Google Scholar
  24. 24.
    Dawley L, Dawley H, Glasgow R, et al. Worksite smoking control, discouragement and cessation. Int J Addict 1993; 28: 719–33PubMedGoogle Scholar
  25. 25.
    Glasgow RE, Hollis JF, Ary DV, et al. Results of a year-long incentives-based worksite smoking cessation program. Addictive Behav 1993; 18: 455–64CrossRefGoogle Scholar
  26. 26.
    Leinweber CE, Macdonald JM, Campbell HS. Community smoking cessation contests: an effective public health strategy. Can J Public Health 1994; 85: 95–8PubMedGoogle Scholar
  27. 27.
    Townsend J, Roderick P, Cooper J. Cigarette smoking by socio-economic group, sex and age: effect of price, income and health publicity. BMJ 1994; 309: 923PubMedCrossRefGoogle Scholar
  28. 28.
    Daykin N. Young women and smoking: towards a sociological account. Health Promot Int 1993; 2: 95–102CrossRefGoogle Scholar
  29. 29.
    Montgomery SM, Cook DG, Bartley MJ, et al. Unemployment, cigarette smoking, alcohol consumption and body weight in young British men. Eur J Public Health 1998; 8: 21–7CrossRefGoogle Scholar
  30. 30.
    Gourlay S, Forbes A, Marriner T, et al. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 1994; 55: 64–9PubMedCrossRefGoogle Scholar
  31. 31.
    Lennox A, Taylor R. Factors associated with outcome in unaided smoking cessation and a comparison of those who have never tried to stop with those who have. Br J Gen Pract 1994; 44: 245–50PubMedGoogle Scholar
  32. 32.
    Haxby D, Sinclair A, Eiff MP, et al. Characteristics and perceptions of nicotine patch users. J Fam Pract 1994; 38: 459–64PubMedGoogle Scholar
  33. 33.
    Nicotine products. In: British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2000 Mar: 243-4Google Scholar
  34. 34.
    Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202PubMedCrossRefGoogle Scholar
  35. 35.
    Anon. Glaxo Wellcome’s new aid to quitting smoking. Pharm J 1999; 263: 936Google Scholar
  36. 36.
    Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patches facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86–99PubMedCrossRefGoogle Scholar
  37. 37.
    Rose JE, Behm F. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug Alcohol Depend 1994; 34: 225–9PubMedCrossRefGoogle Scholar
  38. 38.
    Morrow R, Nepps P, McIntosh M. Silver acetate mouth spray as an aid in smoking cessation: results of a double blind study. J Am Board Fam Pract 1993; 6: 353–7PubMedGoogle Scholar
  39. 39.
    Fant RV, Owen LL, Henningfield JE. Nicotine replacement therapy. Primary Care 1999; 26: 633–54PubMedCrossRefGoogle Scholar
  40. 40.
    Brown RA, Larkin JC, Davis RL. Current concepts in the management of smoking cessation: a review. Am J Man Care 2000; 6: 394–401Google Scholar
  41. 41.
    Fiore M, Smith S, Jorenby D, et al. The effectiveness of the nicotine patch for smoking cessation. Ameta-analysis. JAMA 1994; 271: 1940–7PubMedCrossRefGoogle Scholar
  42. 42.
    Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow-up. BMJ 1999; 318: 285–9PubMedCrossRefGoogle Scholar
  43. 43.
    Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595–600PubMedCrossRefGoogle Scholar
  44. 44.
    Tonnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counselling on the cessation of smoking. N Engl J Med 1988; 318: 15–8PubMedCrossRefGoogle Scholar
  45. 45.
    Niaura R, Goldstein MG, Abrahms DB. Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement. Prev Med 1994; 23: 70–7PubMedCrossRefGoogle Scholar
  46. 46.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRefGoogle Scholar
  47. 47.
    Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. Thorax 1998; 53 Suppl. 5: S1–38CrossRefGoogle Scholar
  48. 48.
    Russell MAH, Wilson C, Taylor C, et al. Effect of general practitioners’ advice against smoking. BMJ 1979; 2: 231–5PubMedCrossRefGoogle Scholar
  49. 49.
    Russell MAH, Merriman R, Stapleton J, et al. Effect of nicotine chewing gum as an adjunct to general practitioners advice against smoking. BMJ 1983; 287: 1782–5PubMedCrossRefGoogle Scholar
  50. 50.
    Russell MAH, Stapleton JA, Jackson PH, et al. Strict program to reduce smoking — effect of clinic supported brief intervention by general-practitioners. BMJ 1987; 295: 1240–4PubMedCrossRefGoogle Scholar
  51. 51.
    Jimenez-Ruiz C, Kunze M, Fagerstrom KO. Nicotine replacement: a new approach to reducing tobacco-related harm. Eur Respir J 1998; 11: 473–9PubMedCrossRefGoogle Scholar
  52. 52.
    Lam W, Sze PC, Sacks HS, et al. Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet 1987; II: 27–30CrossRefGoogle Scholar
  53. 53.
    Waranch HR, Henningfield JE, Edmunds M. Elimination of nicotine gum use. Lancet 1988; I: 49–50CrossRefGoogle Scholar
  54. 54.
    Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990; 153: 699–707PubMedGoogle Scholar
  55. 55.
    Hurt RD, Offord KP, Lauger GG, et al. Cessation of long-term nicotine gun use-a prospective, randomized trial. Addiction 1995; 90: 407–13PubMedCrossRefGoogle Scholar
  56. 56.
    Coleman T, Lakhani M, Wilson A. Managing smoking cessation. BMJ 1999; 318: 138–9PubMedCrossRefGoogle Scholar
  57. 57.
    Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general-practice — randomized controlled trial of transdermal nicotine patches. BMJ 1993; 306: 1308–12PubMedCrossRefGoogle Scholar
  58. 58.
    Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498–529PubMedCrossRefGoogle Scholar
  59. 59.
    Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: towards an integrative model of change. J Consult Clin Psychol 1983; 51: 390–5PubMedCrossRefGoogle Scholar
  60. 60.
    Sinclair H, Bond C, Lennox AS, et al. An evaluation of a training workshop for pharmacists based on the Stages of Change model of smoking cessation. Health Ed J 1997; 56: 296–312CrossRefGoogle Scholar
  61. 61.
    Hudmon KS, Berger BA. Pharmacy applications of the transtheoretical model in smoking cessation. Am J Health Syst Pharm 1995; 52: 282–7PubMedGoogle Scholar
  62. 62.
    Nuffield Committee of Inquiry into Pharmacy. A report of the Nuffield Foundation. London: Nuffield Foundation, 1985Google Scholar
  63. 63.
    Working for patients [White Paper]. London: Her Majesty’s Stationery Office, 1989Google Scholar
  64. 64.
    Pharmaceutical care: the future for community pharmacy. Report of the Joint Working Party on the future role of community pharmaceutical services. London: Royal Pharmaceutical Society of Great Britain on behalf of the Department of Health and the Pharmaceutical Profession, 1992Google Scholar
  65. 65.
    World Health Organisation (WHO). International guide: pharmacies and smoking cessation. Copenhagen: WHO, 1993Google Scholar
  66. 66.
    Anon. Medicines, ethics and practice: a guide for pharmacists. London: Royal Pharmaceutical Society of GreatBritain, 1999 JulGoogle Scholar
  67. 67.
    Baluch WM. Pharmacists’ role in a smoking cessation program at a health maintenance organization. Am J Health-Syst Pharm 1995; 52: 287–93PubMedGoogle Scholar
  68. 68.
    Gauen SE, Lee NL. Pharmacists’ role in a smoking cessation program at a managed health care organization. Am J Health-Syst Pharm 1995; 52: 294–6PubMedGoogle Scholar
  69. 69.
    Smith MD, McGhan WF, Lauger G. Pharmacist counseling and outcomes of smoking cessation. Am Pharm 1995; NS35: 20–9PubMedGoogle Scholar
  70. 70.
    Anderson C. A controlled study of the effect of a health promotion training scheme on pharmacists’ advice about smoking cessation. J Soc Admin Pharm 1995; 12: 115–22Google Scholar
  71. 71.
    Sonderskov J, Olsen J, Sabroe S, et al. Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997; 145: 309–18PubMedCrossRefGoogle Scholar
  72. 72.
    Isacson D, Bingefors C, Ribohn M. Quit smoking at the pharmacy: an evaluation of a smoking cessation programme in Sweden. J Soc Admin Pharm 1998; 15: 164–73Google Scholar
  73. 73.
    Sinclair HK, Bond CM, Lennox AS, et al. Training pharmacists and pharmacy assistants in the stage-of change model of smoking cessation: a randomised controlled trial in Scotland. Tobacco Control 1998; 7: 253–61PubMedCrossRefGoogle Scholar
  74. 74.
    Crealey GE, McElnay JC, Maguire TA, et al. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 1998; 14: 323–33PubMedCrossRefGoogle Scholar
  75. 75.
    Jamrozik K, Vessey M, Fowler G, et al. Controlled trial of three different anti-smoking interventions in general practice. BMJ 1984; 28: 1499–502CrossRefGoogle Scholar
  76. 76.
    Elixhauser A. The costs of smoking and cost-effectiveness of smoking-cessation programs. J Public Health Policy 1990; 11: 218–37PubMedCrossRefGoogle Scholar
  77. 77.
    Phillips D, Kawachi I, Tilyard M. The costs of smoking revisited. NZ Med J 1992; 102: 240–3Google Scholar
  78. 78.
    McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health-Syst Pharm 1996; 53: 45–52PubMedGoogle Scholar
  79. 79.
    Haxby DG, Baldwin R. The economics of smoking cessation. Am J Health-Syst Pharm 1996; 53: 77–9PubMedGoogle Scholar
  80. 80.
    Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. BMJ 1999; 318: 182–5PubMedCrossRefGoogle Scholar
  81. 81.
    Ferry LH, Grissino LM, Runfola PS. Tobacco dependence curricula in US undergraduate medical education. JAMA 1999; 282: 825–9PubMedCrossRefGoogle Scholar
  82. 82.
    Hudmon KS, Prokhorov AV, Corelli RL, et al. Helping tobacco users to quit; pharmacists’ counselling role. Presented at the American Society for Preventive Oncology; 24th Annual Meeting; 2000 Mar, Bethesda (MD)Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • James C. McElnay
    • 1
  • Terry A. Maguire
    • 1
  • Ashlinn Drummond
    • 1
  • Carmel M. Hughes
    • 1
  1. 1.School of PharmacyThe Queen’s University of BelfastBelfastNorthern Ireland

Personalised recommendations